JP2022506072A5 - - Google Patents
Info
- Publication number
- JP2022506072A5 JP2022506072A5 JP2021523230A JP2021523230A JP2022506072A5 JP 2022506072 A5 JP2022506072 A5 JP 2022506072A5 JP 2021523230 A JP2021523230 A JP 2021523230A JP 2021523230 A JP2021523230 A JP 2021523230A JP 2022506072 A5 JP2022506072 A5 JP 2022506072A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- epcam
- seq
- antibody fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862751530P | 2018-10-26 | 2018-10-26 | |
| US62/751,530 | 2018-10-26 | ||
| US201962824539P | 2019-03-27 | 2019-03-27 | |
| US62/824,539 | 2019-03-27 | ||
| US201962846297P | 2019-05-10 | 2019-05-10 | |
| US62/846,297 | 2019-05-10 | ||
| PCT/US2019/057569 WO2020086665A1 (en) | 2018-10-26 | 2019-10-23 | Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506072A JP2022506072A (ja) | 2022-01-17 |
| JP2022506072A5 true JP2022506072A5 (cg-RX-API-DMAC7.html) | 2022-10-31 |
| JP7592009B2 JP7592009B2 (ja) | 2024-11-29 |
Family
ID=70331831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523230A Active JP7592009B2 (ja) | 2018-10-26 | 2019-10-23 | EpCAM抗体、活性化可能抗体、および免疫複合体、ならびにそれらの使用 |
Country Status (22)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4359438A1 (en) * | 2021-06-21 | 2024-05-01 | Bristol-Myers Squibb Company | Use of sucrose, mannitol and glycine to reduce reconstitution time of high concentration lyophilized biologics drug products |
| EP4496816A1 (en) | 2022-03-23 | 2025-01-29 | CytomX Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス,インク. | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| EP4504782A2 (en) | 2022-04-01 | 2025-02-12 | CytomX Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| CN119630428A (zh) | 2022-07-12 | 2025-03-14 | 西托姆克斯治疗公司 | Epcam免疫缀合物及其用途 |
| TW202424184A (zh) | 2022-08-01 | 2024-06-16 | 美商Cytomx生物製藥公司 | 蛋白酶可切割部分及其使用方法 |
| AR130077A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Substratos escindibles por proteasas, y métodos de uso de los mismos |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス,インク. | プロテアーゼ切断性部分及びその使用方法 |
| US20260015425A1 (en) | 2022-08-01 | 2026-01-15 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| CN120958015A (zh) | 2023-04-12 | 2025-11-14 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| EP4694934A1 (en) | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
| WO2026161794A1 (en) | 2025-01-27 | 2026-07-30 | Cytomx Therapeutics, Inc. | Epcam immunoconjugates and therapeutic uses thereof |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| CN1678625A (zh) * | 2002-07-01 | 2005-10-05 | 比奥根艾迪克Ma公司 | 人源化抗淋巴毒素β受体的抗体 |
| EP1542723B1 (en) | 2002-08-16 | 2011-02-23 | ImmunoGen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| WO2007027935A2 (en) | 2005-08-31 | 2007-03-08 | The Regents Of The University Of California | Cellular libraries of peptide sequences (clips) and methods of using the same |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| UA101142C2 (ru) * | 2006-03-17 | 2013-03-11 | Байоджэн Айдэк Ма Инк. | Способ разработки антитела |
| PT2032606E (pt) | 2006-05-30 | 2014-02-05 | Genentech Inc | Anticorpos e imunoconjugados e respetivas utilizações |
| PT2019104E (pt) | 2007-07-19 | 2013-12-03 | Sanofi Sa | Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica |
| EP2190861A4 (en) | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| UA108598C2 (xx) | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
| NZ588884A (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Cross-linkers and their uses |
| WO2010033279A2 (en) | 2008-06-04 | 2010-03-25 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| CA3014224C (en) | 2009-02-05 | 2022-05-24 | Immunogen, Inc. | Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives |
| MX2011010469A (es) | 2009-04-08 | 2012-03-14 | Deutsches Krebsforsch | Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer. |
| GB0909904D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| MX368648B (es) | 2010-04-15 | 2019-10-09 | Seattle Genetics Inc | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas. |
| SI2675480T1 (sl) | 2011-02-15 | 2019-05-31 | Immunogen, Inc. | Metode priprave konjugatov |
| WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| US9790274B2 (en) * | 2013-03-14 | 2017-10-17 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases |
| PL3177643T3 (pl) * | 2014-08-04 | 2019-09-30 | F.Hoffmann-La Roche Ag | Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T |
| SG11201701565PA (en) * | 2014-09-03 | 2017-03-30 | Immunogen Inc | Conjugates comprising cell-binding agents and cytotoxic agents |
| CR20170111A (es) | 2014-09-03 | 2017-05-23 | Immunogen Inc | Derivados de benzodiazepina citotóxicos |
| EP3189057A1 (en) | 2014-09-03 | 2017-07-12 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| WO2016145349A1 (en) * | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Methods of treatment for epcam positive bladder cancer |
| HUE057285T2 (hu) * | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| BR112017023872A2 (pt) | 2015-05-04 | 2018-07-24 | Cytomx Therapeutics Inc | anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos |
| CA2990785C (en) * | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
| SI3313845T1 (sl) | 2015-06-29 | 2021-01-29 | Immunogen, Inc. | Konjugati spremenjenih protiteles cisteina |
| EP3328897A1 (en) * | 2015-07-31 | 2018-06-06 | Sutro Biopharma, Inc. | ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EPCAM ANTIBODIES |
| PT3328894T (pt) * | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
-
2019
- 2019-10-22 TW TW108138004A patent/TWI897855B/zh active
- 2019-10-23 SG SG11202103949SA patent/SG11202103949SA/en unknown
- 2019-10-23 MX MX2021004808A patent/MX2021004808A/es unknown
- 2019-10-23 EP EP26151295.8A patent/EP4736955A3/en active Pending
- 2019-10-23 BR BR112021007918-1A patent/BR112021007918A2/pt unknown
- 2019-10-23 SI SI201931016T patent/SI3873512T1/sl unknown
- 2019-10-23 EP EP19876033.2A patent/EP3873512B1/en active Active
- 2019-10-23 KR KR1020217015710A patent/KR20210095874A/ko active Pending
- 2019-10-23 WO PCT/US2019/057569 patent/WO2020086665A1/en not_active Ceased
- 2019-10-23 US US17/288,469 patent/US20210403594A1/en active Pending
- 2019-10-23 HR HRP20260107TT patent/HRP20260107T1/hr unknown
- 2019-10-23 DK DK19876033.2T patent/DK3873512T3/da active
- 2019-10-23 CA CA3117548A patent/CA3117548A1/en active Pending
- 2019-10-23 PT PT198760332T patent/PT3873512T/pt unknown
- 2019-10-23 CN CN201980084482.4A patent/CN113194985A/zh active Pending
- 2019-10-23 RS RS20260229A patent/RS67852B1/sr unknown
- 2019-10-23 FI FIEP19876033.2T patent/FI3873512T3/fi active
- 2019-10-23 JP JP2021523230A patent/JP7592009B2/ja active Active
- 2019-10-23 LT LTEPPCT/US2019/057569T patent/LT3873512T/lt unknown
- 2019-10-23 AU AU2019364400A patent/AU2019364400B2/en active Active
- 2019-10-23 PL PL19876033.2T patent/PL3873512T3/pl unknown
- 2019-10-23 SM SM20260125T patent/SMT202600125T1/it unknown
-
2021
- 2021-04-20 IL IL282496A patent/IL282496A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7191134B2 (ja) | Igf-1r抗体および癌処置のためのアドレッシングビヒクルとしてのその使用 | |
| US11219693B2 (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| AU2016344663B2 (en) | Composition for the treatment of IGF-1R expressing cancer | |
| AU2015250759B2 (en) | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | |
| JP7579991B2 (ja) | 抗ネクチン-4抗体エキサテカンコンジュゲート | |
| WO2021136483A1 (en) | Anti-trop2 antibodies, antibody-drug conjugates, and application of the same | |
| TWI822740B (zh) | 抗her2雙互補位抗體-藥物結合物及使用方法 | |
| JP2022008618A (ja) | Muc1に特異的に結合する抗体及びその用途 | |
| TW202100557A (zh) | 雙互補位FR-α抗體及免疫結合物 | |
| CN113412281B (zh) | Btn3a结合蛋白及其用途 | |
| JP2022512778A5 (cg-RX-API-DMAC7.html) | ||
| JP2019533719A5 (cg-RX-API-DMAC7.html) | ||
| JP2019503167A (ja) | Cd38に対する抗原結合性ポリペプチド | |
| US10400037B2 (en) | Binding molecules, especially antibodies, binding to L1CAM (CD171) | |
| RU2019129839A (ru) | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты | |
| JP2024520188A5 (cg-RX-API-DMAC7.html) | ||
| JP7728595B2 (ja) | 二重特異性抗体及びその用途 | |
| JP2023543493A5 (cg-RX-API-DMAC7.html) | ||
| JP2024523885A5 (cg-RX-API-DMAC7.html) | ||
| CN117751139A (zh) | 抗Nectin-4抗体依喜替康缀合物 | |
| WO2026082125A1 (zh) | 结合folr1的抗体、含有其的药物及其应用 | |
| HK40104915A (en) | Multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof | |
| HK40041667A (en) | Anti-her2 biparatopic antibody-drug conjugates and methods of use | |
| HK40045878B (en) | Igf-1r antibody and its use as addressing vehicle for the treatment of cancer |